$PFE News

Pfizer (PFE) Gets An Opening In ATTR CM After AstraZeneca Trial Failure

Pfizer Poised for Mixed Second Quarter, RBC Says

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

B of A Securities Maintains Neutral on Pfizer, Lowers Price Target to $26

Jim Cramer on Pfizer: “I Can’t Come Up With Where the Growth Is”

Pfizer And Astellas Win FDA Approval For PADCEV Plus Keytruda As First Platinum-Free Perioperative Treatment For Muscle-Invasive Bladder Cancer

Market Chatter: Pfizer's Vaccine Disputes With Poland, Romania Continue

Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?

‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend

BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board

Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

How Pfizer’s (PFE) Dividend Record Separates Tax Treatment From Business Momentum

JP Morgan Maintains Neutral on Pfizer, Lowers Price Target to $28

2 Healthcare Stocks to Buy for Their Dividends—and Why Pfizer Isn’t One of Them

Opinion: Pfizer's Dividend Is Riskier Than You Might Think

HSBC Downgrades Pfizer (PFE)

Pfizer (PFE) Stock Sinks As Market Gains: Here's Why

Pfizer's Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount